Humacyte (NASDAQ:HUMA) Stock Price Down 3.7%

Humacyte, Inc. (NASDAQ:HUMA)’s stock price was down 3.7% during trading on Monday . The stock traded as low as $5.37 and last traded at $5.43. Approximately 178,347 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 2,186,756 shares. The stock had previously closed at $5.64.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Humacyte in a research report on Tuesday, July 2nd. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. BTIG Research lifted their price objective on shares of Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Benchmark restated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday, September 5th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $8.60.

Humacyte Stock Performance

The company has a market capitalization of $628.76 million, a price-to-earnings ratio of -5.22 and a beta of 1.47. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. The stock has a 50-day simple moving average of $6.94 and a 200-day simple moving average of $5.55.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, analysts anticipate that Humacyte, Inc. will post -1.09 earnings per share for the current year.

Insider Activity at Humacyte

In other news, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Kathleen Sebelius sold 5,182 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the transaction, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Laura E. Niklason sold 277,090 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the sale, the chief executive officer now directly owns 4,029,374 shares of the company’s stock, valued at approximately $26,070,049.78. The disclosure for this sale can be found here. Insiders sold a total of 1,084,153 shares of company stock valued at $6,869,996 over the last three months. 23.10% of the stock is owned by insiders.

Institutional Trading of Humacyte

Several hedge funds have recently made changes to their positions in HUMA. Virtu Financial LLC bought a new stake in Humacyte in the first quarter valued at $197,000. Private Advisor Group LLC boosted its stake in Humacyte by 232.7% during the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after purchasing an additional 222,144 shares during the period. Vanguard Group Inc. boosted its stake in Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares during the period. Victory Capital Management Inc. bought a new position in Humacyte in the 4th quarter worth about $29,000. Finally, Capstone Investment Advisors LLC acquired a new stake in shares of Humacyte in the first quarter valued at approximately $972,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.